Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pazopanib hydrochloride in advanced neuroendocrine tumors; results completed and posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neuroendocrine Tumor G1
• Gastrin-producing Neuroendocrine Tumor
• Lung Carcinoid Tumor
• Multiple Endocrine Neoplasia Type
• Pancreatic Glucagonoma
• Pancreatic Insulinoma
• Pancreatic Neuroendocrine Carcinoma
• Pancreatic Polypeptide Tumor
• Somatostatin-producing Neuroendocrine Tumor

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Status: COMPLETED | Results posted: 2015-04-01